Focused On-demand Library for CXXC-type zinc finger protein 1

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

Our high-tech, dedicated method is applied to construct targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q9P0U4

UPID:

CXXC1_HUMAN

Alternative names:

CpG-binding protein; PHD finger and CXXC domain-containing protein 1

Alternative UPACC:

Q9P0U4; B2RC03; Q8N2W4; Q96BC8; Q9P2V7

Background:

CXXC-type zinc finger protein 1, also known as CpG-binding protein or PHD finger and CXXC domain-containing protein 1, plays a pivotal role in gene expression. It uniquely binds to CpG unmethylated motifs, with a preference for CpGG, acting as a transcriptional activator. This specificity in DNA binding highlights its potential regulatory functions in genomic regions rich in CpG sites.

Therapeutic significance:

Understanding the role of CXXC-type zinc finger protein 1 could open doors to potential therapeutic strategies. Its unique DNA-binding capability suggests a significant function in regulating gene expression, which could be leveraged in designing interventions for diseases where gene regulation is disrupted.